Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?
Status:
Terminated
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Because of the high incidence of post-radiation erectile dysfunction (ED), up to 72% after
external-beam radiotherapy, this patient category represents a most difficult therapeutic
challenge. Therefore, prevention of ED could be more effective than treatment. Tadalafil, a
new phosphodiesterase type 5 inhibitor, has been recently introduced. No studies have
investigated the efficacy of tadalafil in preventing ED in patients undergoing radiotherapy
for prostate cancer. Efficacy of tadalafil can last up to 36 hours after intake. This will
result in a prolonged and continuos enhancement of penile vascular responsiveness. This
randomized, double-blind, placebo-controlled study has been designed to evaluate the efficacy
of 20-mg of tadalafil administered for 12 months in maintaining erectile function of potent
patients undergoing external-beam radiotherapy for prostate cancer.